Mannose Receptor and Targeting Strategies

Jahagirdar, Priyanka; Lokhande, Amit S.; Dandekar, Prajakta; Devarajan, Padma V.

doi:10.1007/978-3-030-29168-6_15

Cited by 15 publications

(15 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Receptor-mediated endocytosis is another important strategy widely employed by researchers to design improved nanotherapeutics by using ligands attached to the nanoparticles that can be recognized by the cells for a site-specific targeted therapy [ 190 ]. In this sense, there exist a plethora of publications regarding nanoencapsulation of antimicrobials in PNs to treat intracellular infections using diverse approaches to promote endocytosis of the PNs and the killing of pathogens by antimicrobials.…”

Section: Recent Advances Of Pns In the Treatment Of Intracellular mentioning

confidence: 99%

“…In this sense, there exist a plethora of publications regarding nanoencapsulation of antimicrobials in PNs to treat intracellular infections using diverse approaches to promote endocytosis of the PNs and the killing of pathogens by antimicrobials. These strategies include PNs using polymers as a delivery platform, PNs in which the polymer itself possesses antimicrobial properties and novel approaches such as hybrid platforms, smart materials, ligand-based functionalized PNs, lipid polymer hybrid nanoparticles and antimicrobial photodynamic therapy ( Figure 5 ) [ 4 , 46 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 ].…”

Section: Recent Advances Of Pns In the Treatment Of Intracellular mentioning

confidence: 99%

“…One typical example of a hybrid strategy involves the encapsulation of metallic nanoparticles with antimicrobial properties within a polymeric platform [ 203 , 204 ]. Most of the strategies use biodegradable and biocompatible polymers and copolymers with PEG and different polyelectrolytes and glyconanoparticles, including CS and its derivatives [ 4 , 45 , 51 , 60 , 64 , 190 , 201 ]. Representative examples that show recent advances on PNs to treat intracellular infections are as follows and summarized in Table 3 .…”

Section: Recent Advances Of Pns In the Treatment Of Intracellular mentioning

confidence: 99%

“…Another tendency in recent studies about site-specific therapies for infected macrophages inducing an immune response is exploiting the C-type lectin superfamily receptors. They are an essential target to be used in antimicrobial therapy because of their expression on the surface of many intracellular pathogens [ 190 , 210 , 231 ]. Particularly, the mannose receptor (CD206) has been involved in abundant studies of antimicrobial therapy based on PNs.…”

Section: Recent Advances Of Pns In the Treatment Of Intracellular mentioning

confidence: 99%

See 3 more Smart Citations

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

2020

View full text Add to dashboard Cite

Polymeric nanocarriers (PNs) have demonstrated to be a promising alternative to treat intracellular infections. They have outstanding performance in delivering antimicrobials intracellularly to reach an adequate dose level and improve their therapeutic efficacy. PNs offer opportunities for preventing unwanted drug interactions and degradation before reaching the target cell of tissue and thus decreasing the development of resistance in microorganisms. The use of PNs has the potential to reduce the dose and adverse side effects, providing better efficiency and effectiveness of therapeutic regimens, especially in drugs having high toxicity, low solubility in the physiological environment and low bioavailability. This review provides an overview of nanoparticles made of different polymeric precursors and the main methodologies to nanofabricate platforms of tuned physicochemical and morphological properties and surface chemistry for controlled release of antimicrobials in the target. It highlights the versatility of these nanosystems and their challenges and opportunities to deliver antimicrobial drugs to treat intracellular infections and mentions nanotoxicology aspects and future outlooks.

show abstract

Section: Recent Advances Of Pns In the Treatment Of Intracellular mentioning

confidence: 99%

Section: Recent Advances Of Pns In the Treatment Of Intracellular mentioning

confidence: 99%

Section: Recent Advances Of Pns In the Treatment Of Intracellular mentioning

confidence: 99%

Section: Recent Advances Of Pns In the Treatment Of Intracellular mentioning

confidence: 99%

See 2 more Smart Citations

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

2020

View full text Add to dashboard Cite

show abstract

“…30−32 Moreover, authoritative reports have demonstrated that Man not only leads to tumor growth hysteresis but can also induce tumor cell apoptosis when combined with doxorubicin (DOX). 28,30 In addition, Man has outstanding biocompatibility, biodegradability, and nonimmunogenicity, and hence it can be skillfully used in biomedical applications such as chemotherapy, gene therapy, and immunotherapy. 28,32,33 Even so, Man is still subject to rapid blood clearance, like other small organic molecules.…”

Section: Introductionmentioning

confidence: 99%

Novel, Self-Distinguished, Dual Stimulus-Responsive Therapeutic Nanoplatform for Intracellular On-Demand Drug Release

et al. 2020

View full text Add to dashboard Cite

On-demand drug release nanoplatforms are promising alternative strategies for enhancing the therapeutic effect of cancer chemotherapy. However, these nanoplatforms still have many drawbacks including rapid blood clearance, nontargeted specificity, and a lack of immune escape function. Even worse, they are also hindered via the dosage-limiting toxicity of traditional chemotherapeutic drugs. Herein, both dual-functional mannose (enhances the antitumor activity of chemotherapeutic drugs and exhibits an innate affinity against the lectin receptor) and amphiphilic d-α-tocopheryl polyethylene glycol 1000 succinate were selected to be covalently linked via a redox-responsive monothioether linkage. The synthesized self-distinguished polymer (TSM), as a structural motif, can be self-assembled into nanoparticles (TSM NPs) in an aqueous solution, in which doxorubicin (DOX) is loaded by weak interactions (TSM–DOX NPs). These TSM–DOX NPs can provide targeted, on-demand drug release under dual stimuli from lysosomal acidity and glutathione (GSH). In addition, TSM–DOX NPs can be self-distinguished via tumor cells in vitro and specifically self-distinguished from the tumor site in vivo. Further in vitro and in vivo research consistently demonstrated that TSM–DOX NPs display highly synergistic chemotherapeutic effects. Taken together, the data show that the self-distinguished GSH-responsive polymer TSM has the potential to load various therapeutic agents.

show abstract